How to Determine Glycan Profiles of Biopharmaceuticals from Peptide Mapping Data
Applications | 2021 | BrukerInstrumentation
Glycosylation is a critical quality attribute of therapeutic proteins and influences their stability, activity, and immunogenicity. Traditional glycan analysis involves enzymatic release and labeling, which sacrifices site-specific information and requires specialized workflows.
This work introduces a streamlined approach to determine glycan compositions directly from tryptic peptide mapping data, leveraging ion mobility PASEF and a novel heated electrospray source. The goals include:
Sample Preparation
Proteins were reduced, alkylated, and digested with trypsin. The resulting peptides were separated by reversed-phase UHPLC and analyzed by timsTOF Pro using PASEF with a reduced precursor threshold.
Data Analysis
Initial peptide mapping was performed in BioPharma Compass, focusing on a 5–15 min retention time window enriched in Fc glycopeptides. MS/MS spectra were searched with GlycoQuest against the GlycO database, treating the tryptic peptide as a mass tag. Stringent thresholds (score > 40, fragmentation coverage > 40%, intensity coverage > 40%) ensured high-confidence assignments.
The workflow identified 36 distinct glycan compositions from NISTmAb tryptic digest, including complex, hybrid, and high-mannose structures. Neutral and acidic glycans eluted at different retention times. The most abundant glycan (G0F) was detected with high intensity, while low-abundance species were identified over a 100:1 dynamic range. Comparison with established labeled-glycan methods confirmed 27 of 30 expected compositions and revealed additional low-abundance structures.
This approach can be extended to glycoproteins with multiple sites, such as viral spike proteins, to achieve site-specific glycan mapping in high throughput. Advances in isomer separation, enhanced fragmentation techniques, and automated data interpretation will further strengthen glycoproteomic analyses.
Direct glycopeptide analysis via PASEF-equipped timsTOF Pro and heated ESI simplifies glycan profiling, retains critical site information, and matches the performance of traditional workflows, offering a powerful tool for biopharmaceutical CQA.
Ion Mobility, LC/TOF, LC/HRMS, LC/MS, LC/MS/MS
IndustriesPharma & Biopharma
ManufacturerBruker
Summary
Importance of the Topic
Glycosylation is a critical quality attribute of therapeutic proteins and influences their stability, activity, and immunogenicity. Traditional glycan analysis involves enzymatic release and labeling, which sacrifices site-specific information and requires specialized workflows.
Study Objectives and Overview
This work introduces a streamlined approach to determine glycan compositions directly from tryptic peptide mapping data, leveraging ion mobility PASEF and a novel heated electrospray source. The goals include:
- Retaining glycosylation site information
- Eliminating separate glycan release and labeling steps
- Utilizing standard peptide mapping datasets
Methodology
Sample Preparation
Proteins were reduced, alkylated, and digested with trypsin. The resulting peptides were separated by reversed-phase UHPLC and analyzed by timsTOF Pro using PASEF with a reduced precursor threshold.
Data Analysis
Initial peptide mapping was performed in BioPharma Compass, focusing on a 5–15 min retention time window enriched in Fc glycopeptides. MS/MS spectra were searched with GlycoQuest against the GlycO database, treating the tryptic peptide as a mass tag. Stringent thresholds (score > 40, fragmentation coverage > 40%, intensity coverage > 40%) ensured high-confidence assignments.
Used Instrumentation
- timsTOF Pro mass spectrometer
- VIP-HESI heated ESI source
- Elute UHPLC system
- Acquity CSH C18 column (2.1×100 mm, 1.7 μm)
- BioPharma Compass 2021b software
- GlycoQuest search engine
Main Results and Discussion
The workflow identified 36 distinct glycan compositions from NISTmAb tryptic digest, including complex, hybrid, and high-mannose structures. Neutral and acidic glycans eluted at different retention times. The most abundant glycan (G0F) was detected with high intensity, while low-abundance species were identified over a 100:1 dynamic range. Comparison with established labeled-glycan methods confirmed 27 of 30 expected compositions and revealed additional low-abundance structures.
Benefits and Practical Applications
- Generates comprehensive glycan profiles within standard peptide mapping runs
- Preserves site-specific glycosylation information
- Delivers high sensitivity and dynamic range using PASEF and VIP-HESI
- Accessible to non-experts for QC and R&D purposes
Future Trends and Applications
This approach can be extended to glycoproteins with multiple sites, such as viral spike proteins, to achieve site-specific glycan mapping in high throughput. Advances in isomer separation, enhanced fragmentation techniques, and automated data interpretation will further strengthen glycoproteomic analyses.
Conclusion
Direct glycopeptide analysis via PASEF-equipped timsTOF Pro and heated ESI simplifies glycan profiling, retains critical site information, and matches the performance of traditional workflows, offering a powerful tool for biopharmaceutical CQA.
Reference
- Hinneburg et al J Am Soc Mass Spectrom 2016
- Hilliard et al mAbs 2017
- Meier et al Mol Cell Proteomics 2018
- Gstöttner et al Anal Chem 2021
Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.
Similar PDF
Glycopeptide Characterization for Various Monoclonal Antibodies Using the Agilent 6545XT AdvanceBio LC/Q-TOF
2019|Agilent Technologies|Applications
Application Note Biotherapeutics and Biosimilars Glycopeptide Characterization for Various Monoclonal Antibodies Using the Agilent 6545XT AdvanceBio LC/Q-TOF Author David L. Wong Agilent Technologies, Inc. Introduction Monoclonal antibodies (mAbs) and their derivatives represent a very complex but important class of biopharmaceutical…
Key words
glycopeptides, glycopeptidesglycan, glycanmapping, mappingglycopeptide, glycopeptidemab, mabadvancebio, advancebiopeptide, peptideassaymap, assaymaptkpreeqynstyr, tkpreeqynstyrbravo, bravohilic, hilicpeptides, peptideswere, weremabs, mabscolumn
Glycan Analysis - Agilent BioHPLC Columns Application Compendium
2020|Agilent Technologies|Guides
Agilent-NISTmAb Glycan Analysis Agilent BioHPLC Columns Application Compendium Contents Agilent-NISTmAb Standard (P/N 5191-5744; 5191-5745) was aliquoted from NISTmAb RM 8671 batch. Quality control (QC) testing is performed using Agilent LC-MS system. QC batch release test includes aggregate profile, charge variants…
Key words
glycan, glycanpage, pagecontents, contentsback, backglycans, glycansadvancebio, advancebiomab, mabinstantpc, instantpcmapping, mappingfld, fldmonoclonal, monoclonaleluent, eluentagilent, agilenthilic, hilicfluorescence
Agilent BioHPLC Columns - Characterization of NIST Monoclonal Antibody Critical Quality Attributes - Application Compendium
2019|Agilent Technologies|Guides
Agilent BioHPLC Columns Characterization of NIST Monoclonal Antibody Critical Quality Attributes Application Compendium Contents Agilent-NISTmAb Standard (P/N 5191-5744; 5191-5745) was aliquoted from NISTmAb RM 8671 batch. Quality control (QC) testing is performed using Agilent LC-MS system. QC batch release test…
Key words
mab, mabglycan, glycanadvancebio, advancebiocounts, countsmapping, mappingpeptide, peptideagilent, agilentmonoclonal, monoclonalglycans, glycansmin, mincolumn, columnmass, massprotein, proteinnistmab, nistmabassaymap
In Depth Analysis of Host Cell Proteins from Antibody Preparations using PASEF
2018|Bruker|Applications
In Depth Analysis of Host Cell Proteins from Antibody Preparations using PASEF Introduction In the rapidly expanding arena of biotherapeutic analysis and bioprocess development, the analysis of host cell proteins (HCPs) at the ppm level is critical. ELISA is currently…
Key words
pasef, pasefhcps, hcpsbisphosphate, bisphosphatealdolase, aldolasenistmab, nistmabtims, timstimstof, timstofunreported, unreportedpeptides, peptidesfructose, fructosegranulins, granulinsmap, maphcp, hcpmobility, mobilitykda